Exclusive collaboration agreement for the development of an algae-based oral delivery vaccine

This agreement will surely pave the road for TransAlgae technology recognition and use for the benefit of the animal cultivation industry
January 31, 2021
Exclusive collaboration agreement for the development of an algae-based oral delivery vaccine

TransAlgae microalgae-based oral delivery vaccine technology eliminates unnecessary labor and loss of animal life due to stress while reducing the cost and time consumption associated with today’s injectable vaccines.

TransAlgae which aims to shape the future of vaccination in the field of aquaculture with its disruptive microalgae-based oral delivery technology is proud to announce the finalization and signing of an exclusive business development collaboration agreement with Virbac, a French company and one of the leading animal health players worldwide.

Founded more than fifty years ago, Virbac is the sixth-largest animal health company worldwide, with 33 subsidiaries and a presence in more than 100 countries. Virbac has acted under the banner of innovation to deliver a practical range of products and services to diagnose, prevent and treat the majority of pathologies, all while improving the quality of life for animals.

The companies have signed an exclusive collaboration agreement to develop a vaccine based on TransAlgae's break-through technology and are engaged together in a long term business relationship.
 
“This agreement is a vote of confidence in the oral delivery technology of TransAlgae by one of the global leaders in the veterinary sector and will surely pave the road for TransAlgae technology recognition and use for the benefit of the animal cultivation industry.” Said Maor Sasson, CEO at TransAlgae.

To date, effective and efficient oral delivery in animal health has been one of the veterinary sector’s biggest challenges. TransAlgae’s technology aims to solve this challenge by utilizing microalgae for two important purposes; A production site for the transferred sequence and a delivery vehicle for the transcripted expressed molecule.

The microalgae are produced without any antibiotics and in fermenters under a controlled environment enabling rapid, low-cost production that can be practiced anywhere on the globe.

This agreement is expected to deliver revolutionary change to the world of vaccination by enabling an effective elegant industrialized vaccination method. TransAlgae microalgae-based oral delivery technology eliminates unnecessary labor and loss of animal life due to stress while reducing costs and time consumption associated with today’s injectable vaccines.

About TransAlgae
Founded in 2008, TransAlgae, an Israeli biotech company, has developed a breakthrough technology, using genetically engineered algae as the vehicle to orally deliver therapeutic drugs such as vaccines and insecticides in their intact and functional form for Human Pharma, Animal Health and Crop Protection. 

More Articles :